Platelet function variability and non-genetic causes

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Trials

Background:

• Dual antiplatelet therapy (DAPT) is a cornerstone in managing coronary artery disease (CAD), particularly post-acute coronary syndromes and interventions.
• A significant subset of patients exhibit diminished therapeutic response to clopidogrel, a key antiplatelet agent.
• This non-responsiveness is attributed to complex extrinsic and intrinsic mechanisms, impacting clinical outcomes.

Purpose of the Study:

• To highlight the clinical significance of clopidogrel non-responsiveness in patients with coronary artery disease.
• To identify both genetic and non-genetic factors contributing to variable responses to clopidogrel therapy.
• To emphasize the need for further research to elucidate drug interactions and identify predictors of non-responsiveness.

Main Methods:

• Review of existing data on dual antiplatelet therapy and clopidogrel responsiveness.
• Identification of known genetic variability affecting antiplatelet therapy response.
• Analysis of non-genetic factors including drug interactions and co-morbidities.

Main Results:

• Clopidogrel non-responsiveness is linked to severe cardiovascular complications.
• Non-genetic factors, including interactions with proton-pump inhibitors, statins, and co-morbidities like diabetes and renal failure, significantly influence clopidogrel efficacy.
• Genetic variability also plays a role in patient response to antiplatelet therapy.

Conclusions:

• Understanding and addressing clopidogrel non-responsiveness is critical for optimizing DAPT in CAD management.
• Further large-scale clinical trials employing standardized methods are essential to pinpoint specific drug interactions and reliable predictors of clopidogrel non-responsiveness.
• Personalized antiplatelet strategies may be required to mitigate risks associated with variable patient responses.